Apeloa TPD/PROTAC Platform offers comprehensive services for the development of targeted protein degradation therapeutics, including PROteolysis Trgeting Chimeras (PROTACs). With over 80 PROTAC-focused scientists and two dynamic chemistry service teams located in Boston and Hengdian, the platform provides expertise throughout the entire PROTAC development process. From target validation, hit generation, lead optimization, to clinical development, Apeloa leverages its integrated parallel synthesis platform, extensive E3 ligand, linker, and POI binder intermediate libraries, and strong analytical and ADME capabilities to drive PROTAC projects forward efficiently.

Apeloa TPD/PROTAC Platform is led by a team of highly experienced scientists, including co-inventors of two approved NDAs and one Phase II IND. The team comprises 12 Ph.D. holders with a combined synthetic chemistry experience of over 100 years, and a tot